David J. Serisier - Concepedia

Author

David J. Serisier

Also Known As

D J Serisier, D Serisier, D. J. Serisier, D. Serisier, D.J. Serisier, DAVID J. SERISIER, David J Serisier, David J. SERISIER, David J. Serisier, David SERISIER

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Mater Adult Hospital The University of Queensland Mater Research Mater Health Services King's College London

About

David J. Serisier is an author at Mater Adult Hospital specializing in medicine, pulmonary fibrosis, and clinical microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	933
2	Health Sciences	3	3	174
3	Engineering	1	1	55
4	Applied Physiology	1	1	19
5	Epidemiology	1	1	140

David J. Serisier

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Effect of Long-term, Low-Dose Erythromycin on Pulmonary Exacerbations Among Patients With Non–Cystic Fibrosis Bronchiectasis David J. Serisier, Megan Martin, Michael A. McGuckin, JAMA	2013	399
Characterization of Bacterial Community Diversity in Cystic Fibrosis Lung Infections by Use of 16S Ribosomal DNA Terminal Restriction Fragment Length Polymorphism Profiling Geraint B. Rogers, M. P. Carroll, David J. Serisier, Journal of Clinical Microbiology Progressive LossGeneticsKlebsiella PneumoniaePathologyMedical Microbiology	2004	310
Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial David J. Serisier, Diana Bilton, Anthony De Soyza, Thorax	2013	243
A Novel Microbiota Stratification System Predicts Future Exacerbations in Bronchiectasis Geraint B. Rogers, Nur Masirah M. Zain, Kenneth D. Bruce, Annals of the American Thoracic Society	2014	232
The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial Geraint B. Rogers, Kenneth D. Bruce, Megan Martin, The Lancet Respiratory Medicine Respiratory Microbiota CompositionNon-cystic Fibrosis BronchiectasisPlacebo-controlled Bless TrialInfectious Respiratory DiseasePulmonary Fibrosis	2014	226
Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition Geraint B. Rogers, Chris Gast, Leah Cuthbertson, Thorax	2013	209
Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques Pierre Amarenco, Stephen M. Davis, E. Jones, Stroke	2014	195
Use of 16S rRNA Gene Profiling by Terminal Restriction Fragment Length Polymorphism Analysis To Compare Bacterial Communities in Sputum and Mouthwash Samples from Patients with Cystic Fibrosis Geraint B. Rogers, M. P. Carroll, David J. Serisier, Journal of Clinical Microbiology	2006	145
Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases David J. Serisier The Lancet Respiratory Medicine AsthmaInflammatory Lung DiseaseAntibioticsLung InflammationHealth Sciences	2013	140
Matrix Metalloproteinases Vary with Airway Microbiota Composition and Lung Function in Non–Cystic Fibrosis Bronchiectasis Steven Taylor, Geraint B. Rogers, Alice C.–H. Chen, Annals of the American Thoracic Society	2015	94

Page 1